Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mersana Therapeutics ( (MRSN) ) just unveiled an update.
On July 24, 2025, Mersana Therapeutics announced a 1-for-25 reverse stock split of its common stock to comply with Nasdaq’s minimum bid price requirement. This corporate action, effective July 25, 2025, aims to consolidate shares and adjust equity incentive plans, with trading on a post-split basis commencing July 28, 2025.
The most recent analyst rating on (MRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Mersana Therapeutics stock, see the MRSN Stock Forecast page.
Spark’s Take on MRSN Stock
According to Spark, TipRanks’ AI Analyst, MRSN is a Neutral.
Mersana Therapeutics faces significant financial challenges with a negative equity position and persistent losses, which are the most impactful factors. While recent positive clinical data and debt settlements offer some optimism, strategic restructuring and valuation concerns weigh heavily on the overall score.
To see Spark’s full report on MRSN stock, click here.
More about Mersana Therapeutics
Mersana Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company aims to address unmet needs in oncology with its proprietary platforms and pipeline of ADC candidates.
Average Trading Volume: 2,776,643
Technical Sentiment Signal: Sell
Current Market Cap: $50.55M
Find detailed analytics on MRSN stock on TipRanks’ Stock Analysis page.